NCT04541979View on ClinicalTrials.gov

Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

January 11, 2022

Study Completion Date

January 6, 2023

Conditions
COVID-19
Interventions
DRUG

aerosolized DNase

DNase

DRUG

NaCl

NaCl 0.9%, isotonic saline

Trial Locations (1)

Unknown

Lund ED, Lund

All Listed Sponsors
lead

Region Skane

OTHER

NCT04541979 - Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 | Biotech Hunter | Biotech Hunter